Premium
Plasma Aβ biomarker associated with cognitive decline in preclinical Alzheimer’s disease
Author(s) -
Lim Yen Ying,
Maruff Paul T.,
Kaneko Naoki,
Fowler Christopher J.,
Villemagne Victor L.L.,
Kato Takashi,
Rowe Christopher C.,
Arahata Yutaka,
Iwamoto Shinichi,
Ito Kengo,
Tanaka Koichi,
Yanagisawa Katsuhiko,
Masters Colin L.,
Nakamura Akinori
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.045884
Subject(s) - biomarker , episodic memory , cognition , cognitive decline , medicine , psychology , oncology , clinical psychology , disease , gerontology , dementia , psychiatry , chemistry , biochemistry
Background Using immunoprecipitation‐mass spectrometry, we recently developed and validated a plasma composite biomarker for the assessment of Aβ levels. However, as yet, it’s utility to predict clinical and cognitive outcomes remains unclear. This study aimed to examine the relationship between this plasma Aβ composite biomarker and cognitive function in cognitively normal older adults in two independent cohorts. Method This is a longitudinal study conducted in two independent cohorts – the Australian imaging, Biomarkers and Lifestyle (AIBL) study and Japan’s National Centre for Geriatrics and Gerontology (NCGG) study. A series of linear mixed models were conducted to determine the relationships between plasma Aβ composite scores and cognitive decline. Cognitively normal (CN) older adults enrolled in the AIBL study (n=156) and the NCGG study (n=57) were included in this analysis. Participants had undergone Aβ neuroimaging using positron emission tomography (PET), cognitive assessments and provided blood samples. We derived a high‐performance plasma Aβ composite biomarker by immunoprecipitation with mass‐spectrometry. The main outcome measures were composites of episodic memory, executive function, language and attention. Result Both continuous and categorical measures of the plasma Aβ composite biomarker were significantly related to decline in episodic memory and executive function (Figure 1). The magnitude of effects of the plasma Aβ composite on episodic memory and executive function were comparable to that observed for the effects of PET Aβ levels on these same outcome measures. Conclusion Several plasma Aβ biomarkers have been developed, but none have yet been applied to investigate their relationship with cognitive outcomes. Our results have important implications for the use of this biomarker in the detection of at‐risk individuals.